BA
GHDX

Boston Advisors’s Genomic Health, Inc. GHDX Stock Holding History

Boston Advisors’s Portfolio GHDX Stock Details GHDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-13,750
Closed -$441K – 684
2017
Q3 		$441K Sell
13,750
-495
-3% -$15.6K 0.01% 513
2017
Q2 		$464K Sell
14,245
-430
-3% -$13.6K 0.01% 505
2017
Q1 		$462K Sell
14,675
-705
-5% -$20.9K 0.01% 484
2016
Q4 		$452K Buy
+15,380
New +$469K 0.01% 502

Other funds holding GHDX

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Boston Advisors's GHDX Position: Q4 2017 in Review

Boston Advisors sold out of Genomic Health, Inc. (GHDX) in Q4 2017, closing a stake of 13,750 shares — an estimated $441K sold.

Boston Advisors first reported a position in GHDX in Q4 2016 and held it in 4 quarters. The position peaked at $464K in Q2 2017. 135 funds tracked by Wall St. Rank hold GHDX as of Q4 2017.

  • Boston Advisors reported no remaining Genomic Health, Inc. position as of Q4 2017 after selling out during the quarter.
  • Boston Advisors sold 13,750 Genomic Health, Inc. shares in Q4 2017, an estimated $441K.
  • Boston Advisors first reported a position in Genomic Health, Inc. in Q4 2016 and held it in 4 quarters.
  • Boston Advisors's Genomic Health, Inc. position peaked at $464K in Q2 2017.
  • 135 funds tracked by Wall St. Rank held Genomic Health, Inc. as of Q4 2017.

Based on Boston Advisors's 13F filing for Q4 2017, filed 24 Jan 2018.